Ranibizumab vs Dexamethasone Implant in Vitrectomized Eyes With Diabetic Macular Edema
Status:
Completed
Trial end date:
2019-04-30
Target enrollment:
Participant gender:
Summary
Vitrectomy is required for removal of vitreous hemorrhage or retinal traction tissue in some
patients with proliferative diabetic retinopathy. Post-vitrectomy macular edema may occur in
these diabetic patients. Intravitreal injections of anti-VEGF agents or corticosteroid are
required for treating diabetic macular edema (DME) in vitrectomized eyes. Intraocular levels
of various cytokines may alter in the diabetic eyes following vitrectomy. Pharmacokinetics
may be different between various intraocular agents in vitrectomized eyes. Herein our study
will prospectively randomize to compare the clinical behavior between intravitreal
ranibizumab (IVR) and intravitreal dexamethasone implant (IDI) in vitrectomized patients with
DME. To our knowledge, it is the first study involving such subject.